ANALIZAN LA EFICACIA DEL PANTOPRAZOL EN LA INFECCION POR <I>HELICOBACTER PYLORI</I>

ANALIZAN LA EFICACIA DEL PANTOPRAZOL EN LA INFECCION POR HELICOBACTER PYLORI

Los distintos inhibidores de la bomba de protones son equivalentes cuando se los utiliza con dos antibióticos para erradicar la infección por Helicobacter pylori.

Autor:
Javier p. Gisbert
Columnista Experto de SIIC

Institución:
Hospital Universitario de la Princesa, Universidad Autonoma de Madrid

Artículos publicados por Javier p. Gisbert

Recepción del artículo
14 de Febrero, 2006

Aprobación
14 de Febrero, 2006

Primera edición
23 de Junio, 2006

Segunda edición, ampliada y corregida
7 de Junio, 2021

ANALIZAN LA EFICACIA DEL PANTOPRAZOL EN LA INFECCION POR HELICOBACTER PYLORI

Resumen
Los inhibidores de la bomba de protones (IBP) son, globalmente, más eficaces que los antagonistas H₂ cuando ambos antisecretores se administran -a las dosis habituales- junto con antibióticos con la intención de erradicar la infección por Helicobacter pylori. Un reciente metaanálisis, que compara pantoprazol frente a otros IBP (como omeprazol o lansoprazol) como tratamiento para erradicar H. pylori, concluye que los resultados son equivalentes independientemente del IBP utilizado. Así, a partir de los 7 estudios incluidos en dicho metaanálisis, en los que 534 pacientes fueron tratados con pantoprazol y 603 con otros IBP, la tasa media de erradicación de H. pylori fue de 83% y de 81%, respectivamente. El odds ratio para esta comparación fue exactamente de 1 (intervalo de confianza del 95%, 0.61-1.64). Una vez tomada la decisión de emplear un IBP (combinado con antibióticos) en el tratamiento para erradicar H. pylori, cabría plantearse la pregunta de si todos los IBP son igual de eficaces dentro de las terapias triples. En este sentido, en la II Conferencia Española de Consenso sobre el tratamiento para erradicar H. pylori, celebrada recientemente, se concluyó que todos los IBP (omeprazol, lansoprazol, pantoprazol, rabeprazol y esomeprazol) son equivalentes cuando se utilizan con dos antibióticos para erradicar la infección por H. pylori.

Palabras clave
inhibidor de la bomba de protones, omeprazol, pantoprazol, Helicobacter pylori, tratamiento

Artículo completo
(castellano)
Extensión: +/-8.06 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Gastroenterología
Relacionadas: Farmacología, Infectología, Medicina Farmacéutica, Medicina Interna

Enviar correspondencia a:
Javier P. Gisbert, 28669, Playa de Mojácar 29, Urb. Bonanza, Boadilla del Monte, Madrid, España

Bibliografía del artículo
1. Mones J, Gisbert JP, Borda F, Domínguez-Muñoz E. Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference. Rev Esp Enferm Dig 2005; 97:348-74.
2. Gisbert JP, Calvet X, Gomollon F, Mones J. Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference. Med Clin (Barc) 2005; 125:301-16.
3. Gisbert JP, Pajares JM. Helicobacter pylori therapy: first-line options and rescue regimen. Dig Dis 2001; 19:134-43.
4. Hentschel E, Brandstatter G, Dragosics B, Hirschl AM, Nemec H, Schutze K, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer [see comments]. N Engl J Med 1993; 328:308-12.
5. Goh KL, Parasakthi N, Chuah SY, Toetsch M. Combination amoxycillin and metronidazole with famotidine in the eradication of Helicobacter pylori -a randomized, double-blind comparison of a three times daily and twice daily regimen. Eur J Gastroenterol Hepatol 1997; 9:1091-5.
6. Yousfi MM, El-Zimaity HM, Cole RA, Genta RM, Graham DY. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Aliment Pharmacol Ther 1996; 10:119-22.
7. Drake IM, Axon TT, Clarke AH. Ranitidine in a twice daily triple-therapy regimen for the eradication of Helicobacter pylori [see comments]. Eur J Gastroenterol Hepatol 1996; 8:1169-73.
8. Breuer T, Kim JG, el-Zimaity HM, Nakajima S, Ota H, Osato M, et al. Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea [published erratum appears in Aliment Pharmacol Ther 1999 Apr;13(4):567]. Aliment Pharmacol Ther 1997; 11:939-42.
9. Gschwantler M, Dragosics B, Wurzer H, Brandstatter G, Weiss W. Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxicillin and clarithromycin. Eur J Gastroenterol Hepatol 1998; 10:579-82.
10. Hulten K, Jaup B, Stenquist B, Engstrand L. Combination treatment with ranitidine is highly efficient against Helicobacter pylori despite negative impact of macrolide resistance. Helicobacter 1997; 2:188-93.
11. Lo WC, Lin HJ, Wang K, Perng CL, Lee SD. Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. Chung Hua I Hsueh Tsa Chih (Taipei) 1997; 59:171-6.
12. Gotz JM, Veenendaal RA, Veselic M, Bernards S, Lamers CB. Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. Scand J Gastroenterol Suppl 1995; 212:34-7.
13. Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol 2001; 15:413-31.
14. Savarino V, Sandro Mela G, Zentilin P, Vigneri S, Celle G. Acid inhibition and amoxicillin activity against Helicobacter pylori [letter; comment]. Am J Gastroenterol 1993; 88:1975-6.
15. Sakaguchi M, Ashida K, Umegaki E, Miyoshi H, Katsu K. Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. J Clin Gastroenterol 1995; 20:S27-31.
16. Holtmann G, Layer P, Goebell H. [Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons (see comments)]. Z Gastroenterol 1996; 34:267-72.
17. Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 18:757-66.
18. Adamek RJ, Labenz J. Ranitidine/amoxicillin vs omeprazole/amoxicillin for cure of H. pylori-positive gastric ulcer: Role of acid suppression. Gastroenterology 1995; 108:A44.
19. Borody TJ, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995; 37:477-81.
20. Cataldo MG, Brancato D, Donatelli M, Morici ML, Aspetti S, Spina P. Treatment of patients with duodenal ulcer positive for Helicobacter pylori infection: ranitidine or omeprazole associated with colloidal bismuth subcitrate plus amoxicillin. Curr Ther Res 1996; 57:168-174.
21. Ell C, Schoerner C, Solbach W, Stolte M, Vieth M, Ridl W, et al. The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2001; 13:685-91.
22. Grigoriev PY, Zoseeva OV, Jakovenko AV, Jakovenko WP. Zantac (ranitidine) - antimicrobial therapy vs omeprazole - antimicrobial therapy for Helicobacter pylori (HP) associated peptic ulcer (PU). Am J Gastroenterol 1994; 89:1392.
23. Gschwantler M, Dragosics B, Schutze K, Wurzer H, Hirschl AM, Pasching E, et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori-a randomized, controlled trial. Aliment Pharmacol Ther 1999; 13:1063-9.
24. Hsu CC, Chen JJ, Hu TH, Lu SN, Changchien CS. Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2001; 13:921-6.
25. Lamouliatte H. Controlled study of omeprazole-amoxicillin-tinidazole vs. ranitidine-amoxicillin-tinidazole in Helicobacter pylori associated duodenal ulcers (DU), final and long-term results. Ital J Gastroenterol 1991; 23(suppl.2):9.
26. Lazzaroni M, Bargiggia S, Porro GB. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol 1997; 92:649-52.
27. Mosca S, Rocco VP, De Caprio M, Gigliotti T. Comparison of two double therapies (nizatidine plus amoxicilline v/s omeprazole plus amoxicilline) in patients with Helicobacter pylori positive duodenal ulcer. Gut 1995; 37(suppl.2):A226.
28. Murakami K, Sato R, Kubota T, Fujioka T, Nasu M. Effects of new triple therapy regimens of inhibition of gastric acid secretion and eradication of Helicobacter pylori in a randomized trial. Gastroenterology 1999; 116:A260.
29. Oderda G, Caristo P, Kuvidi M, Lerro P, Ronchi B, Osello R, et al. Evaluation of different treatment schedules in childhood Helicobacter pylori gastritis: a 10 year experience. Gut 1999; 45(suppl.3):A94.
30. Popovic N, Bulajic M, Glisic M, Popovic P, Milosavljevic T, Popovic N, et al. Comparison of two triple therapies (ranitidine plus amoxicilline plus tinidazole v/s omeprazole plus amoxicilline plus tinidazol) in patients with Helicobacter pylori positive duodenal ulcer. Gut 1997; 41(suppl.1):A102.
31. Ruszniewski P, Lamouliatte H, Flejou JF, Megraud F, Slamma A. Evaluation of short-term ranitidine vs omeprazole triple therapy regimens for eradication of Helicobacter pylori (Hp) in duodenal ulcer (DU) patients (pts). Gut 1997; 41(suppl.1):A94.
32. Sacca N, De Medici A, Rodino S, De Siena M, Giglio A. Duodenal ulcer Helicobacter pylori (HP) positive: therapy with ranitidine (R) + clarithromicine (C) + metronidazole (M) versus omeprazole (O) + clarithromicine + metronidazole. Gut 1996; 39(suppl.2):A34.
33. Savarino V, Zentilin P, Bisso G, Pivari M, Mele MR, Mela GS, et al. Head-to-head comparison of 1-week triple regimens combining ranitidine or omeprazole with two antibiotics to eradicate Helicobacter pylori. Aliment Pharmacol Ther 1999; 13:643-9.
34. Shcherbakov PL, Filin VA, Volkov IA, Tatarinov PA, Belousov YB. A randomized comparison of triple therapy Helicobacter pylori eradication regimens in children with peptic ulcers. J Int Med Res 2001; 29:147-53.
35. Spadaccini A, De Fanis C, Sciampa G, Masciulli V, Pantaleone U, Di Virgilio M, et al. Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers. Aliment Pharmacol Ther 1996; 10:829-31.
36. Tham TC, Collins JS, Molloy C, Sloan JM, Bamford KB, Watson RG. Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of Helicobacter pylori. Ulster Med J 1996; 65:131-6.
37. Treiber G, Ammon S, Klotz U. Age-dependent eradication of Helicobacter pylori with dual therapy. Aliment Pharmacol Ther 1997; 11:711-8.
38. Peterson WL. The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11 Suppl 1:21-5.
39. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38:243-70.
40. Van Zanten SJ, Goldie J, Hollingsworth J, Silletti C, Richardson H, Hunt RH. Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol 1992; 45:225-7.
41. Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996; 111:886-900.
42. Alarcón T, Domingo D, Sánchez I, Díaz de Rojas F, López Brea M. In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1996; 15:937-40.
43. Cederbrant G, Kahlmeter G, Schalen C, Kamme C. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother 1994; 34:1025-9.
44. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC, Jr. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8:888-9.
45. Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idstrom JP, Cederberg C, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice [see comments]. Gastroenterology 1996; 111:358-67.
46. Labenz J, Beker JA, Dekker CP, Farley A, Klor HU, Jonsson A. Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11:515-22.
47. Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdorffer E. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997; 11:323-9.
48. Pommerien W, Schultze V, Braden B, Lembcke B, Wrangstadh M, Londong W. Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10:303-8.
49. Bayerdorffer E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108:1412-7.
50. Labenz J, Stolte M, Blum AL, Jorias I, Leverkus F, Sollbohmer M, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37:39-43.
51. Sjostedt S, Sagar M, Lindberg G, Wikstrom B, Nord CE, Seensalu R. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin [see comments]. Scand J Gastroenterol 1998; 33:39-43.
52. Kleveland PM, Waldum HL, Brenna E, Aase S, Maeland JA. Relationship between the efficacy of amoxicillin and intragastric pH for the treatment of Helicobacter pylori infection. Helicobacter 1997; 2:144-8.
53. Van der Hulst RW, Weel JF, Verheul SB, Keller JJ, ten Kate FJ, van der Ende A, et al. Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. Aliment Pharmacol Ther 1996; 10:165-71.
54. Malaty H, El-Zimaity HM, Genta RM, Cole RA, Graham DY. High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10:1001-4.
55. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39:5-12.
56. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole [see comments]. Aliment Pharmacol Ther 1999; 13:719-29.
57. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002; 16:1149-56.
58. Bardhan KD, Dillon J, Axon AT, Cooper BT, Tildesley G, Wyatt JI, et al. Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. Aliment Pharmacol Ther 2000; 14:59-67.
59. Chiba N, Marshall CP. Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori. Can J Gastroenterol 2000; 14:27-31.
60. Megraud F, Boyanova L, Lamouliatte H. Activity of lansoprazole against Helicobacter pylori [letter]. Lancet 1991; 337:1486.
61. Alarcón T, Domingo D, Sánchez I, Sanz JC, Martínez MJ, López Brea M. In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1998; 17:275-7.
62. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14:963-78.
63. Powell KU, Bell GD, Bowden AF, Trowell JE, Jones PH. Helicobacter pylori eradication therapy: a comparison between either omeprazole or ranitidine in combination with amoxycillin plus metronidazole. Br J Clin Res 1995; 6:163-169.
64. Rollan A, Giancaspero R, Acevedo C, Fuster F, Hola K. [Treatment of Helicobacter pylori infection in patients with duodenal ulcer: a cost-benefit study]. Rev Med Chil 2000; 128:367-77.
65. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9:363-78.
66. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51:460-82.
67. Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol 1996; 8 Suppl 1:S15-20.
68. Gisbert JP, Boixeda D, Martín de Argila C, García Plaza A. Papel del pantoprazol en el tratamiento erradicador de Helicobacter pylori. Rev Clin Esp 1998; 198:678-83.
69. Thomson AB. Are the orally administered proton pump inhibitors equivalent? a comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000; 2:482-93.
70. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22:266-80; discussion 265.
71. Jungnickel PW. Pantoprazole: a new proton pump inhibitor. Clin Ther 2000; 22:1268-93.
72. Poole P. Pantoprazole. Am J Health Syst Pharm 2001; 58:999-1008.
73. Suerbaum S, Leying H, Klemm K, Opferkuch W. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori [letter]. Eur J Clin Microbiol Infect Dis 1991; 10:92-3.
74. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998; 3:21-7.
75. Dattilo M, Figura N. Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. J Clin Gastroenterol 1998; 27 Suppl 1:S163-9.
76. Hartmann M, Theiss U, Huber R, Luhmann R, Bliesath H, Wurst W, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10:359-66.
77. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2004; 16:89-99.
78. Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology 1997; 113:S131-48.
79. Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12:823-37.
80. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999; 13:857-64.
81. Gisbert JP, Carpio D, Marcos S, Gisbert JL, Garcia Gravalos R, Pajares JM. One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2000; 12:489-95.
82. Svoboda P, Kantorova I, Ochmann J, Doubek J, Kozumplik L, Marsova J. Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. Hepatogastroenterology 1997; 44:886-90.
83. Adamek RJ, Bethke TD. Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. Am J Gastroenterol 1998; 93:1919-24.
84. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. Am J Gastroenterol 1998; 93:386-9.
85. Dehesa M, Larisch J, Di Silvio M, Dibildox M, Almaguer I, Gonzalez G, et al. Comparison of three seven days pantoprazole (panto) based Helicobacter pylori (Hp) eradication schemes in a mexican population with highly metronidazole (met) resistant Hp strains [abstract]. Gastroenterology 1998; 114:A288.
86. Lamouliatte H, Samoyeau R, De Mascarel A, Megraud F. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999; 13:1523-30.
87. Adamek RJ, Szymanski C, Pfaffenbach B. Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection. Am J Gastroenterol 1997; 92:1949-50.
88. Cammarota G, Papa A, Cianci R, Cannizzaro O, Armuzzi A, Gasbarrini A, et al. Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. Eur J Gastroenterol Hepatol 1999; 11:247-50.
89. Catalano F, Branciforte G, Catanzaro R, Bentivegna C, Cipolla R, Nuciforo G, et al. Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. Helicobacter 1999; 4:178-84.
90. Catalano F, Catanzaro R, Branciforte G, Bentivegna C, Cipolla R, Brogna A, et al. Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up. J Clin Gastroenterol 2000; 31:130-6.
91. Domínguez Martín A, Domínguez Muñoz A, Muñoz S, Alonso JB, González MD. Efficacy of six days triple therapy with pantoprazole plus clarithromycin and amoxycillin versus omeprazole plus clarithromycin and amoxycillin for H. pylori eradication [abstract]. Gastroenterology 1998; 114:A107.
92. Rinaldi V, Zullo A, De Francesco V, Hassan C, Winn S, Stoppino V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999; 13:163-8.
93. Salces I, Soto S, Díaz Tasende J, Castellano G, Yela C, Morillas JD, et al. Estudio comparativo de 3 pautas de erradicación de H. pylori [abstract]. Rev Esp Enferm Dig 2001; 93 (suppl.I):156.

Título español

Resumen

Palabras clave

Bibliografía

Artículo completo
(exclusivo a suscriptores)

Autoevaluación

Tema principal en SIIC Data Bases

Especialidades

English title

Abstract

Key words

Full text
(exclusivo a suscriptores)

Autor

Artículos

Correspondencia

Patrocinio y reconocimiento

Imprimir esta página

Clasificado en

Artículos originales>
Expertos del Mundo

Especialidad principal:
Gastroenterología

Relacionadas:
Farmacología
Infectología
Medicina Farmacéutica
Medicina Interna

Suscripción a siicsalud

Comprar este artículo
Extensión: ± 8.06 páginas impresas en papel A4

Artículos seleccionados para su compra

Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.

ua31618